Physician profile
Danielle E Lann
NPI 1417116682
$19,848.68
in general payments reported to CMS, 2019-2025
18 companies · $6,751 in 2025
The $6,751 reported for 2025 was more than what 89% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $91.23 · 2021: $95.13 · 2022: $493 · 2023: $8,954 · 2024: $3,222 · 2025: $6,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $8,500 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,250 · Food and Beverage: $1,577 · Consulting Fee: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $8,500.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,250.00 |
| Food and Beverage | $1,577.11 |
| Consulting Fee | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $9,612.85 | 2019-2025 | Tepezza, Evenity, Prolia |
| Horizon Therapeutics Plc | $8,800.01 | 2022-2023 | Tepezza |
| Sanofi-Aventis U.S. LLC | $303.18 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $207.24 | 2020-2025 | Unithroid |
| Novo Nordisk INC | $160.80 | 2023-2024 | Sogroya |
| Medtronic Minimed, INC. | $151.41 | 2019 | |
| Embecta Corp. | $135.04 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Abbott Laboratories | $110.72 | 2019-2023 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $99.81 | 2020-2025 | Licart, Tirosint, Flector |
| Ascendis Pharma Endocrinology INC | $52.10 | 2023-2025 | Yorvipath |
| Abbvie INC. | $48.30 | 2023-2024 | |
| Corcept Therapeutics | $42.47 | 2023 | Korlym |
| Eisai INC. | $28.33 | 2019 | |
| Dexcom, INC. | $22.08 | 2024 | Dexcom G6 Transmitter |
| Acera Surgical, INC. | $20.20 | 2025 | Restrata Wound Matrix |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $19.79 | 2020 | |
| Melinta Therapeutics, LLC | $19.35 | 2025 | Orbactiv, Kimyrsa, Rezzayo |
| Alexion Pharmaceuticals, INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Lann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.